Chemokine and adhesion systems

The chemokine and adhesion systems comprise a coordinated network of signaling proteins and cell-surface receptors essential for the directed migration and positioning of cells, particularly within the immune system (Griffith et al., 2014, Annu Rev Immunol) [1]. Chemokines, a family of small cytokines, act as chemoattractants that bind to G protein-coupled receptors (GPCRs) to initiate intracellular signaling and cytoskeletal reorganization (Bachelerie et al., 2014, Pharmacol Rev) [2]. Adhesion molecules, including integrins, selectins, and members of the immunoglobulin superfamily, provide the physical tethering required for cells to roll along, adhere to, and eventually transmigrate through the vascular endothelium into tissues (Ley et al., 2007, Nat Rev Immunol) [3]. This "leukocyte adhesion cascade" is a fundamental process in immune surveillance, wound healing, and the inflammatory response (Springer, 1994, Cell) [4]. Dysregulation of these systems is a hallmark of various pathologies, including chronic inflammatory diseases like rheumatoid arthritis, autoimmune conditions such as multiple sclerosis, and the metastatic spread of cancer cells (Zlotnik and Yoshie, 2012, Immunity) [5]. Therapeutic strategies targeting these systems involve small molecule antagonists or monoclonal antibodies designed to block specific receptor-ligand interactions, thereby inhibiting the recruitment of pathogenic cells to sites of disease (Proudfoot, 2002, Nat Rev Immunol) [6]. For example, drugs like Maraviroc target CCR5 to prevent HIV entry, while Natalizumab targets integrin alpha-4 to treat multiple sclerosis (FDA Drug Labels) [7]. Despite their therapeutic potential, targeting these systems carries risks of systemic immunosuppression and impaired host defense, necessitating careful patient selection and monitoring (Bloomgren et al., 2012, N Engl J Med) [8].

Other names

Leukocyte trafficking systemChemokine-adhesion cascadeCell migration machineryLeukocyte adhesion cascade

Drugs targeting these systems primarily act as competitive antagonists of chemokine receptors or as monoclonal antibodies that block adhesion molecules, preventing the recruitment and extravasation of inflammatory cells into target tissues [6, 7].